Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NC-6004 with 5-FU and Cetuximab in Head and Neck Cancer
NCT02817113Phase 1Terminated
- Sponsor
- Orient EuroPharma
- Start
- Jun 2016
- Primary completion
- Sep 2018
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of demplatin pegraglumer in squamous cell carcinoma of the head and neck (HNSCC), sponsored by Orient EuroPharma. Primary endpoint: Maximum Tolerated Dose at 29 months. Started Jun 2016; status: terminated.
02
Drugs
demplatin pegraglumer
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT02817113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02817113.